Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 100% Improvement Relative Risk HCQ for COVID-19  AbdelGhaffar et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 3,712 patients in Egypt (April - July 2020) Lower mortality with HCQ (p<0.000001) c19hcq.org AbdelGhaffar et al., PLOS ONE, January 2022 Favors HCQ Favors control

Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study

AbdelGhaffar et al., PLOS ONE, doi:10.1371/journal.pone.0262348
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 3,712 hospitalized patients in Egypt, showing lower mortality with HCQ treatment in unadjusted results. According to the official treatment protocol, HCQ was recommended with higher risk and/or more serious cases.
risk of death, 99.9% lower, RR 0.001, p < 0.001, treatment 0 of 238 (0.0%), control 900 of 3,474 (25.9%), NNT 3.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
AbdelGhaffar et al., 11 Jan 2022, retrospective, Egypt, peer-reviewed, 17 authors, study period April 2020 - July 2020.
This PaperHCQAll
Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study
Muhammad M Abdelghaffar, Dalia Omran, Ahmed Elgebaly, Eshak I Bahbah, Shimaa Afify, Mohamed Alsoda, Mohamed El-Shiekh, Enass S Elsayed, Soha S Shaaban, Samah Abdelhafez, Khaled Elkelany, Ayman A Eltayar, Omnia S Ali, Lamiaa Kamal, Ahmed M Heiba, Ahmad El Askary, Hend Ibrahim Shousha
PLOS ONE, doi:10.1371/journal.pone.0262348
We aimed to assess the epidemiological, clinical, and laboratory characteristics associated with mortality among hospitalized Egyptian patients with COVID-19. A multicenter, retrospective study was conducted on all polymerase chain reaction (PCR)-confirmed COVID-19 cases admitted through the period from April to July 2020. A generalized linear model was reconstructed with covariates based on predictor's statistical significance and clinically relevance. The odds ratio (OR) was calculated by using stepwise logistic regression modeling. A total of 3712 hospitalized patients were included; of them, 900 deaths were recorded (24.2%). Compared to survived patients, non-survived patients were more likely to be older than 60 years (65.7%), males (53.6%) diabetic (37.6%), hypertensive (37.2%), and had chronic renal insufficiency (9%). Non-survived patients were less likely to receive azithromycin (p <0.001), anticoagulants (p <0.001), and steroids (p <0.001). We found that age � 60 years old (OR = 2.82, 95% CI 2.05-3.86; p <0.0001), diabetes mellitus (
Supporting information S1
References
Boettler, Marjot, Newsome, Mondelli, Maticic et al., Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic, JHEP Rep, doi:10.1016/j.jhepr.2020.100169
Cao, Li, Feng, Wan, Huang et al., Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov, doi:10.1038/s41421-020-0147-1
Chen, Klein, Garibaldi, Li, Wu et al., Aging in COVID-19: Vulnerability, immunity and intervention, Ageing Res Rev, doi:10.1016/j.arr.2020.101205
Chen, Shan, Qian, Asians Do Not Exhibit Elevated Expression or Unique Genetic Polymorphisms for ACE2, the Cell-Entry Receptor of SARS-CoV-2, doi:10.20944/preprints202002.0258.v2
Chen, Wu, Chen, Yang, Chen, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, doi:10.1136/bmj.m1091
Coperchini, Chiovato, Croce, Magri, Rotondi, The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system, Cytokine Growth Factor Rev, doi:10.1016/j.cytogfr.2020.05.003
Cuker, Peyvandi, Coronavirus disease 2019 (COVID-19): Hypercoagulability
Diabetes, Standards of medical care in diabetes-2011, Diabetes Care, doi:10.2337/dc11-S011
Docherty, Harrison, Green, Hardwick, Pius et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ, doi:10.1136/bmj.m1985
Fung, Yuen, Ye, Chan, Jin, A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses, Emerg. Microbes Infect, doi:10.1080/22221751.2020.1736644
Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein, Impact of sex and gender on COVID-19 outcomes in Europe, Biol Sex Differ, doi:10.1186/s13293-020-00304-9
Griesbeck, Ziegler, Laffont, Smith, Chauveau et al., Sex differences in plasmacytoid dendritic cell levels of Irf5 drive higher Ifn-alpha production in women, J Immunol, doi:10.4049/jimmunol.1501684
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Harrison, Fazio-Eynullayeva, Lane, Underhill, Lip, Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis, PLoS Med, doi:10.1371/journal.pmed.1003321
Hoffmann, Kleine-Weber, Schroeder, Kru ¨ger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736%2820%2930183-5
Inciardi, Lupi, Zaccone, Italia, Raffo et al., Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19), JAMA Cardiol, doi:10.1001/jamacardio.2020.1096
Klein, Pekosz, Park, Ursin, Shapiro et al., Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population, J Clin Invest, doi:10.1172/JCI142004
Kragholm, Andersen, Gerds, Butt, Østergaard et al., Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19)-a Danish nationwide, register-based study, Clin Infect Dis, doi:10.1093/cid/ciaa924
Lim, Bae, Kwon, Nauck, COVID-19 and diabetes mellitus: from pathophysiology to clinical management, Nat Rev Endocrinol, doi:10.1038/s41574-020-00435-4
Mcbane Rd 2nd, Roldan, Niven, Pruthi, Franco et al., Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic, Mayo Clin Proc, doi:10.1016/j.mayocp.2020.08.030
Middleton, Practical use of the Glasgow Coma Scale; a comprehensive narrative review of GCS methodology, Australas Emerg Nurs J, doi:10.1016/j.aenj.2012.06.002
Nasiri, Haddadi, Tahvildari, Farsi, Arbabi et al., COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis, Front Med, doi:10.3389/fmed.2020.00459
O'driscoll, Dos Santos, Wang, Cummings, Azman et al., Age-specific mortality and immunity patterns of SARS-CoV-2, Nature, doi:10.1038/s41586-020-2918-0
Onder, Rezza, Brusaferro, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy, JAMA, doi:10.1001/jama.2020.4683
Pawelec, Age and immunity: what is "immunosenescence"?, Exp. Gerontol, doi:10.1016/j.exger.2017.10.024
Peckham, De Gruijter, Raine, Radziszewska, Ciurtin et al., Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission, Nat Commun, doi:10.1038/s41467-020-19741-6
Petrilli, Jones, Yang, Rajagopalan, Donnell et al., Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, BMJ, doi:10.1136/bmj.m1966
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA, doi:10.1001/jama.2020.6775
Singh, Khan, Liver Disease in United States: A Multi-Center Research Network Study
Tiwari, Khatib, Dixit, Rathore, Melinkeri et al., Anticoagulation in COVID-19: An Update, J Crit Care Med (, doi:10.2478/jccm-2020-0033
Verity, Okell, Dorigatti, Winskill, Whittaker et al., Estimates of the severity of coronavirus disease 2019: a model-based analysis, Lancet Infect Dis, doi:10.1016/S1473-3099%2820%2930243-7
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies, Int J Surg, doi:10.1016/j.ijsu.2014.07.013
Walker, Grint, Strongman, Eggo, Peppa et al., UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records, BMC Public Health, doi:10.1186/s12889-021-10427-2
Williams, Mancia, Spiering, Rosei, Azizi et al., ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J, doi:10.1093/eurheartj/ehy339
Worldometers, None
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Xie, Ma, Tang, Liu, Severe COVID-19: A Review of Recent Progress with a Look toward the future, Front Public Health, doi:10.3389/fpubh.2020.00189
Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.017
Zhang, Wu, Li, Zhao, Wang, Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105954
Zhang, Zhou, Zhu, Song, Feng et al., Immune phenotyping based on the neutrophil-tolymphocyte ratio and igg level predicts disease severity and outcome for patients with COVID-19, Front. Mol. Biosci, doi:10.3389/fmolb.2020.00157
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit